Top

Published in:

01-06-2009 | Original Article

Irinotecan-induced mucositis is associated with changes in intestinal mucins

Authors: Andrea M. Stringer, Rachel J. Gibson, Richard M. Logan, Joanne M. Bowen, Ann S. J. Yeoh, Jessica Laurence, Dorothy M. K. Keefe

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2009

Abstract

Purpose

Mucositis is a major oncological problem, caused by the cytotoxic effects of cancer chemotherapy and radiotherapy. Irinotecan is used to treat a variety of solid tumours, through the inhibition of DNA topoisomerase I and is linked with severe mucositis and diarrhoea. Mucus production appears to be increased, which may contribute to the development of diarrhoea.

Methods

Dark agouti rats were treated with irinotecan, and tissues collected at several time points up to 72 h. Goblet cells and mucin secretion were investigated, as well as mucin expression (Muc2 and Muc4) and kruppel-like factor (Klf) 4 using immunohistochemistry in the gastrointestinal tract. Both goblet cells and cells positive for Muc expression were counted, and analysed statistically using the Mann–Whitney U test with Bonferroni correction.

Results

Goblet cells decreased significantly after irinotecan treatment. However, mucin secretion increased. Mucin expression changed significantly after treatment. Muc2 and Muc4 decreased significantly in the villi of the jejunum after treatment, Muc2 and Muc4 decreased significantly in the crypts. Muc2 decreased significantly in the colon.

Conclusions

Irinotecan causes an increase in mucin secretion and a net decrease in mucin-producing goblet cells, and the expression of Muc2 and Muc4 in the gastrointestinal tract is altered following treatment. Increased mucin secretion is likely to be related to altered mucin expression, and may contribute to chemotherapy-induced diarrhoea.

Pico JL, Avila-Garavito A, Naccache P (1998) Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3(6):446–451PubMed

Keefe DM, Cummins AG, Dale BM, Kotasek D, Robb TA, Sage RE (1997) Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) 92(4):385–389

Keefe DM, Brealey J, Goland GJ, Cummins AG (2000) Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47(5):632–637PubMedCrossRef

Sonis ST (2004) A biological approach to mucositis. J Support Oncol 2(1):21–32 Discussion 5–6PubMed

Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G et al (1995) CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31(7–8):1283–1287CrossRef

Brandi G, Dabard J, Raibaud P, Di Battista M, Bridonneau C, Pisi AM et al (2006) Intestinal microflora and digestive toxicity of irinotecan in mice. Clin Cancer Res 12(4):1299–1307PubMedCrossRef

Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM (2003) Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 18(9):1095–1100PubMedCrossRef

Ikuno N, Soda H, Watanabe M, Oka M (1995) Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 87(24):1876–1883PubMedCrossRef

Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Burns J et al (2007) Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) 232(1):96–106

10.

Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E et al (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56(16):3752–3757PubMed

11.

Smith NF, Figg WD, Sparreboom A (2006) Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20(2):163–175PubMedCrossRef

12.

Saegusa Y, Ichikawa T, Iwai T, Goso Y, Okayasu I, Ikezawa T et al (2007) Changes in the mucus barrier of the rat during 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol. 5:1–7

13.

Specian RD, Oliver MG (1991) Functional biology of intestinal goblet cells. Am J Physiol 260(2 Pt 1):C183–C193PubMed

14.

Robbe C, Capon C, Coddeville B, Michalski JC (2004) Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract. Biochem J 384(Pt 2):307–316PubMed

15.

Kurosumi K, Shibuichi I, Tosaka H (1981) Ultrastructural studies on the secretory mechanism of goblet cells in the rat jejunal epithelium. Arch Histol Jpn 44(3):263–284PubMed

16.

Smirnov A, Sklan D, Uni Z (2004) Mucin dynamics in the chick small intestine are altered by starvation. J Nutr 134(4):736–742PubMed

17.

Katz JP, Perreault N, Goldstein BG, Lee CS, Labosky PA, Yang VW et al (2002) The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development 129(11):2619–2628PubMed

18.

Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM (2008) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 62(1):33–41PubMedCrossRef

19.

Gibson RJ, Bowen JM, Keefe DM (2005) Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 116(3):464–470PubMedCrossRef

20.

Barcelo A, Claustre J, Moro F, Chayvialle JA, Cuber JC, Plaisancie P (2000) Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. Gut 46(2):218–224PubMedCrossRef

21.

Elting LS, Cooksley CD, Chambers MS, Garden AS (2007) Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68(4):1110–1120PubMed

22.

Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84(6):697–702PubMed

23.

Takasuna K, Hagiwara T, Watanabe K, Onose S, Yoshida S, Kumazawa E et al (2006) Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea. Cancer Chemother Pharmacol 25:1–10

24.

Bowen JM, Stringer AM, Gibson RJ, Yeoh AS, Hannam S, Keefe DM (2007) VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 6(9):1449–1454PubMedCrossRef

25.

Laboisse C, Jarry A, Branka JE, Merlin D, Bou-Hanna C, Vallette G (1996) Recent aspects of the regulation of intestinal mucus secretion. Proc Nutr Soc 55(1B):259–264PubMedCrossRef

26.

Plaisancie P, Barcelo A, Moro F, Claustre J, Chayvialle JA, Cuber JC (1998) Effects of neurotransmitters, gut hormones, and inflammatory mediators on mucus discharge in rat colon. Am J Physiol 275(5 Pt 1):G1073–G1084PubMed

27.

McConalogue K, Furness JB (1994) Gastrointestinal neurotransmitters. Baillieres Clin Endocrinol Metab 8(1):51–76PubMedCrossRef

28.

Leitao RF, Ribeiro RA, Bellaguarda EA, Macedo FD, Silva LR, Oria RB et al (2007) Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 59(5):603–612PubMedCrossRef

29.

Logan R, Gibson R, Bowen J, Stringer A, Sonis ST, Keefe D (2008) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 62:33–41PubMedCrossRef

30.

Oliver MG, Specian RD (1990) Cytoskeleton of intestinal goblet cells: role of actin filaments in baseline secretion. Am J Physiol 259(6 Pt 1):G991–G997PubMed

Title: Irinotecan-induced mucositis is associated with changes in intestinal mucins
Authors: Andrea M. Stringer
Rachel J. Gibson
Richard M. Logan
Joanne M. Bowen
Ann S. J. Yeoh
Jessica Laurence
Dorothy M. K. Keefe
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0855-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2009

Anticancer activities of sesquiterpene lactones from Cyathocline purpurea in vitro

Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies

Role of copper transporters in resistance to platinating agents

Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects

Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form

Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer